Zurich-based healthcare data management and analytics company BC Platforms on Thursday announced that its partnership with Euformatics and Oncompass Medicine has been awarded a contract to develop standardized oncology workflows for a buyer consortium of seven major European hospitals.
The consortium consists of hospitals from the Medical University of Graz in Austria, University of Florence and University of Milano-Bicocca in Italy, Erasmus University Medical Center in the Netherlands, Christian-Albrecht University of Kiel and St. Anna Children’s Cancer Research Institute in Germany, and the Centre Léon Bérard in France.
The contract marks the second phase of the partnership’s Instand-NGS4P project, a Horizon 2020-funded project with the mission of improving cancer diagnostics by developing and providing integrated and standardized workflows for next generation sequencing (NGS). The project aims to support medical decision-making through integrating information from cancer gene testing, pharmacogenetics testing, and e-medication.
BC Platforms formed the partnership with the Finnish firm Euformatics and Hungarian Oncompass to implement the project.
The project is planned to run in three phases until May 2025, with a total precommercial procurement budget of approximately 8 million euros ($8.2 million).
